248 related articles for article (PubMed ID: 22505276)
1. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism.
Zein CO; Lopez R; Fu X; Kirwan JP; Yerian LM; McCullough AJ; Hazen SL; Feldstein AE
Hepatology; 2012 Oct; 56(4):1291-9. PubMed ID: 22505276
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feldstein AE; Lopez R; Tamimi TA; Yerian L; Chung YM; Berk M; Zhang R; McIntyre TM; Hazen SL
J Lipid Res; 2010 Oct; 51(10):3046-54. PubMed ID: 20631297
[TBL] [Abstract][Full Text] [Related]
3. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Zein CO; Yerian LM; Gogate P; Lopez R; Kirwan JP; Feldstein AE; McCullough AJ
Hepatology; 2011 Nov; 54(5):1610-9. PubMed ID: 21748765
[TBL] [Abstract][Full Text] [Related]
4. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.
Van Wagner LB; Koppe SW; Brunt EM; Gottstein J; Gardikiotes K; Green RM; Rinella ME
Ann Hepatol; 2011; 10(3):277-86. PubMed ID: 21677329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
6. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
Bell LN; Wang J; Muralidharan S; Chalasani S; Fullenkamp AM; Wilson LA; Sanyal AJ; Kowdley KV; Neuschwander-Tetri BA; Brunt EM; McCullough AJ; Bass NM; Diehl AM; Unalp-Arida A; Chalasani N;
Hepatology; 2012 Oct; 56(4):1311-8. PubMed ID: 22532269
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet.
Yalniz M; Bahçecioğlu IH; Kuzu N; Celebi S; Ataseven H; Ustündağ B; Ozercan IH; Sahin K
Dig Dis Sci; 2007 Sep; 52(9):2380-6. PubMed ID: 17415655
[TBL] [Abstract][Full Text] [Related]
9. Pentoxifylline does not prevent neither liver damage nor early profibrogenic events in a rat model of non-alcoholic steatohepatitis.
Vial P; Riquelme A; Pizarro M; Solís N; Madariaga JA; Aguayo G; Duarte I; Soza A; Accatino L; Arrese M
Ann Hepatol; 2006; 5(1):25-9. PubMed ID: 16531961
[TBL] [Abstract][Full Text] [Related]
10. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates.
Waddington EI; Croft KD; Sienuarine K; Latham B; Puddey IB
Atherosclerosis; 2003 Mar; 167(1):111-20. PubMed ID: 12618275
[TBL] [Abstract][Full Text] [Related]
13. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
14. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
15. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
[TBL] [Abstract][Full Text] [Related]
16. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.
Wu J; Zhao MY; Zheng H; Zhang H; Jiang Y
Acta Pharmacol Sin; 2010 Oct; 31(10):1367-75. PubMed ID: 20835270
[TBL] [Abstract][Full Text] [Related]
17. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.
Alkhouri N; Berk M; Yerian L; Lopez R; Chung YM; Zhang R; McIntyre TM; Feldstein AE; Hazen SL
Dig Dis Sci; 2014 Jul; 59(7):1617-24. PubMed ID: 24464211
[TBL] [Abstract][Full Text] [Related]
18. Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) -- preliminary findings.
Oliveira CP; Faintuch J; Rascovski A; Furuya CK; Bastos Mdo S; Matsuda M; Della Nina BI; Yahnosi K; Abdala DS; Vezozzo DC; Alves VA; Zilberstein B; Garrido AB; Halpern A; Carrilho FJ; Gama-Rodrigues JJ
Obes Surg; 2005 Apr; 15(4):502-5. PubMed ID: 15946429
[TBL] [Abstract][Full Text] [Related]
19. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
